Postmortem analysis of quetiapine and pregabalin in human bone.
Forensic toxicology
Gas chromatography–mass spectrometry
Human bone
Pregabalin
Quetiapine
Journal
Legal medicine (Tokyo, Japan)
ISSN: 1873-4162
Titre abrégé: Leg Med (Tokyo)
Pays: Ireland
ID NLM: 100889186
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
24
10
2019
revised:
11
03
2020
accepted:
06
05
2020
pubmed:
23
5
2020
medline:
8
9
2020
entrez:
23
5
2020
Statut:
ppublish
Résumé
In this study quetiapine and pregabalin were analyzed in human bones. A method previously developed for the determination of antidepressants in human bone was tested for the analysis of these two substances. Bones were pulverized and subjected to the extraction protocol, and after undergoing solid-phase extraction, samples were analyzed using gas chromatography-mass spectrometry. The assay was validated in the range 0.3-500 ng/mg, mean analytical recovery was 76.9% for quetiapine and 90.9% for pregabalin, matrix effect was 83% for quetiapine and 91% for pregabalin and process efficiency was 63.8% for quetiapine and 82.7% for pregabalin. The intra- and inter-day precision was below 3% in all cases and the intra- and inter-assay accuracy values were in almost all cases better than 12%. The validated method was then applied to bone samples from forensic cases. Drugs were detected in bone in 2 of the 3 blood positive cases. The approximate concentrations in bone were 40 ng/mg for pregabalin and 7 ng/mg for quetiapine. To our knowledge, this is the first time these substances were detected in bones. With this study the number of substances with a validated protocol to be used in human bones in case of necessity is expanded.
Identifiants
pubmed: 32442861
pii: S1344-6223(20)30051-1
doi: 10.1016/j.legalmed.2020.101717
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Pregabalin
55JG375S6M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101717Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.